HTLV-1 and HTLV-2 prevalence in the United States.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Prevalence of human T-lymphotropic virus type 1 and 2 (HTLV-1/-2) infection in pregnant women in Brazil: a systematic review and meta-analysis.Scientific reports · 2021
   Pooled it
2. Re-emergence of human T-lymphotropic viruses in West Africa.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
   Pooled it
3. Viral oncogenes drive biphenotypic lymphoproliferative malignancy in transgenic mice.Scientific reports · 2025
   Article
4. HTLV-1 and ATLL: Epidemiology, Oncogenesis, and Opportunities for Community-Informed Research in the United States.Viruses · 2025
   Review
5. Human T-Lymphotropic Virus (HTLV): Epidemiology, Genetic, Pathogenesis, and Future Challenges.Viruses · 2025
   Review
6. YTHDF1 and YTHDC1 mJournal of virology · 2025
   Article
7. Successfully treated acute adult T-cell leukemia with haploidentical stem cell transplantation.Proceedings (Baylor University. Medical Center) · 2022
   Article
8. A role for an HTLV-1 vaccine?Frontiers in immunology · 2022
   Review
9. Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers.Infectious agents and cancer · 2020
   Review
10. p30 protein: a critical regulator of HTLV-1 viral latency and host immunity.Retrovirology · 2019
    Review
11. Human T cell leukemia virus type 1 and Zika virus: tale of two reemerging viruses with neuropathological sequelae of public health concern.Journal of neurovirology · 2019
    Review
12. Seroepidemiology of HTLV-1 and HTLV-2 Infection in Neyshabur City, North-Eastern Iran, during 2010-2014.Iranian biomedical journal · 2017
    Article
13. Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppresors and failure of antiretrovirals.Therapeutic advances in infectious disease
    Article
14. Origin and prevalence of human T-lymphotropic virus type 1 (HTLV-1) and type 2 (HTLV-2) among indigenous populations in the Americas.Revista do Instituto de Medicina Tropical de Sao Paulo
    Review

Corrections and comments

• Comment on
  Seroprevalence and demographic determinants of human T-lymphotropic virus type 1 and 2 infections among first-time blood donors--United States, 2000-2009.2014

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as